Skip to main content
. Author manuscript; available in PMC: 2019 Jan 17.
Published in final edited form as: Vaccine. 2009 Mar 13;27(12):1811–1815. doi: 10.1016/j.vaccine.2009.01.094

Fig. 1.

Fig. 1.

Protection against anthrax infection is optimized by adding Dalbavancin to CpG-adjuvanted AVA. A/J mice were challenged with 30 LD50 of Sterne strain anthrax spores on day 0. Animals were treated once i.p. with 150 μg of Dalbavancin (□), 10 μl of AVA + 20 μg of CpG ODN (▲), or both (●) in the period from 30 days before to 3 days after challenge. Survival was monitored for 3 weeks. Data represent the combined results from three independent experiments involving a total of 10–18 mice/group. *p < .02 comparing combination therapy with either single therapy.